

Cenobamate (Ontozry®) Information for Community Pharmacies

Background

Cenobamate (Ontozry®) is licensed for the adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite treatment with at least 2 anti-epileptic medicinal products.¹

NICE TA 753 recommends cenobamate as an option for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least 2 antiseizure medicines. ² It is recommended only if it is used as an add-on treatment, after at least 1 other add-on treatment has not controlled seizures, and treatment is started in a tertiary epilepsy service.

Cenobamate has recently been assigned an amber classification on the <u>Barnsley formulary</u> for use in line with the NICE TA and the <u>South Yorkshire and Bassetlaw Adult Epilepsy Shared</u> Care Guideline.

This information has been produced to support community pharmacies with the ordering of cenobamate to ensure continuity of supply for patients in response to feedback that some patients are experiencing difficulties in obtaining in the community.

Ordering Information

Cenobamate (Ontozry®) is currently only available from Phoenix Healthcare.³ Pharmacies who currently hold Phoenix Accounts may order via the Phoenix Reordering System or by calling Customer Services.

Alternatively, pharmacies who hold accounts with both Alliance and Phoenix can order via Alliance using the Third Party Ordering System (TPOS). It is also anticipated that pharmacies who hold accounts with both AAH and Phoenix will be able to order via AAH using TPOS in the near future.

If a pharmacy does not currently hold a Phoenix Account please contact Customer Services via the contact details below.

Phoenix Contact Information

General Customer Services (order status/delivery queries/order placement):

Tel: 0844 736 2287

Email: customerservice@phoenixmedical.co.uk

Web Portal (pharmacy and Doctors): https://www.myp-i-n.co.uk/pms/design/hframe.htm

Date Approved: August 2022 (minor update November 2022) Review Date: August 2025

PIP Codes

Product Description	PIP Code
Cenobamate Ontozry 12.5mg 1x14 & 25mg 1x14 Tablets 28	6773691
Cenobamate Ontozry 50mg tablets 1x14 Tablets 14	6773683
Cenobamate Ontozry 50mg tablets 2x14 Tablets 28	6773675
Cenobamate Ontozry 100mg tablets 1x14 Tablets 14	6773667
Cenobamate Ontozry 100mg tablets 2x14 Tablets 28	6773642
Cenobamate Ontozry 150mg tablets 1x14 Tablets 14	6773634
Cenobamate Ontozry 150mg tablets 2x14 Tablets 28	6773659
Cenobamate Ontozry 200mg tablets 1x14 Tablets 14	6773626
Cenobamate Ontozry 200mg tablets 2x14 Tablets 28	6773618

Further Information

Should a pharmacy require further information or encounter any issues in ordering the medication, please liaise with a member of the Medicines Management Team (either linked to the GP practice or alternatively contact the central team on 01226 433798) who can advise and/or support the patient in obtaining the medication from an alternative pharmacy as necessary.

References

- Ontozry® SPC. Available at: https://www.medicines.org.uk/emc/product/13010/smpc. Date accessed<1st August 2022>.
- NICE TA 753. Cenobamate for treating focal onset seizures in epilepsy (December 2021). Available at: https://www.nice.org.uk/guidance/ta753. Date accessed <1st August 2022>.
- 3. Information provided by Angelini Pharma.

This information was endorsed by Barnsley Area Prescribing Committee on 10th August 2022 and 9th November 2022.

Date Approved: August 2022 (minor update November 2022) Review Date: August 2025